Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder

Having linked its glucagon/GLP-1 candidate to a significant reduction in heavy drinking days, Altimmune is preparing to speak to the FDA in December about the design of a Phase 3 program.